18F‐FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor‐Positive Breast Cancer: A Retrospective Comparative Study with 18F‐FDG PET/CT

Conclusion.Performing 18F‐FES PET/CT in newly diagnosed ER‐positive breast cancer patients increases the value of diagnosis equivocal lesions and treatment management compared with 18F‐FDG PET/CT.Implications for Practice.This study investigated whether 16a‐18F‐fluoro‐17b‐estradiol (18F‐FES) positron emission tomography (PET)/computed tomography (CT) affects the clinical management of patients with newly diagnosed estrogen receptor (ER)‐positive breast cancer. Physicians completing two questionnaires comparing the clinical impact of 18F‐FES and 18F‐FDG on individual management plans in patients with newly diagnosed ER‐positive breast cancer confirmed that 18F‐FES scans led to change in management in 26.3% of the 19 patients with newly diagnosed ER positive breast cancer. This retrospective study indicates the potential impact of 18F‐FES PET/CT on intended management of patients with newly diagnosed estrogen receptor positive breast cancer in comparison to 18F‐fluoro‐2‐deoxy‐D‐glucose PET/CT.

Source: The Oncologist - December 9, 2019 Category: Cancer & Oncology Authors: Cheng Liu, Chengcheng Gong, Shuai Liu, Yingjian Zhang, Yongping Zhang, Xiaoping Xu, Huiyu Yuan, Biyun Wang, Zhongyi Yang Tags: Breast Cancer Source Type: research